{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:17:54Z","timestamp":1787811474328,"version":"build-2784847793"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00393-026-01776-7","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:18:58Z","timestamp":1772713138000},"page":"395-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapy with mycophenolate mofetil, nintedanib, and tocilizumab in a\u00a0patient with progressive systemic sclerosis-associated interstitial lung disease","Kombinationstherapie mit Mycophenolat-Mofetil, Nintedanib und Tocilizumab bei einer Patientin mit einer mit progressiver systemischer Sklerose assoziierten interstitiellen Lungenerkrankung"],"prefix":"10.1007","volume":"85","author":[{"given":"Liangyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"3","key":"1776_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas\u00a0A, Silver\u00a0RM, Arrossi\u00a0AV, Highland\u00a0KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8(3):304\u2013320. https:\/\/doi.org\/10.1016\/S2213-2600(19)30480-1","journal-title":"Lancet Respir Med"},{"key":"1776_CR2","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211032437","volume":"13","author":"KE Konopka","year":"2021","unstructured":"Konopka\u00a0KE, Myers\u00a0JL (2021) Interstitial lung disease pathology in systemic sclerosis. Ther Adv Musculoskelet Dis 13:1759720X211032437. https:\/\/doi.org\/10.1177\/1759720X211032437","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"2","key":"1776_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu\u00a0G, Montesi\u00a0SB, Silver\u00a0RM et\u00a0al (2024) Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 209(2):137\u2013152. https:\/\/doi.org\/10.1164\/rccm.202306-1113ST","journal-title":"Am J Respir Crit Care Med"},{"key":"1776_CR4","doi-asserted-by":"publisher","unstructured":"Del Galdo\u00a0F, Lescoat\u00a0A, Conaghan\u00a0PG et\u00a0al (2024) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Disard-2024-226430. https:\/\/doi.org\/10.1136\/ard-2024-226430","DOI":"10.1136\/ard-2024-226430"},{"key":"1776_CR5","doi-asserted-by":"crossref","unstructured":"Johnson, S. R., Bernstein, E. J., Bolster, M. B  et al (2024). 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & rheumatology (Hoboken, N.J.), 76(8), 1201\u20131213. https:\/\/doi.org\/10.1002\/art.42860","DOI":"10.1002\/art.42860"},{"key":"1776_CR6","doi-asserted-by":"crossref","unstructured":"Johnson, S. R., Bernstein, E. J., Bolster, M. B et al (2024). 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis & rheumatology (Hoboken, N.J.), 76(8), 1182\u20131200. https:\/\/doi.org\/10.1002\/art.42861","DOI":"10.1002\/art.42861"},{"key":"1776_CR7","doi-asserted-by":"crossref","unstructured":"Antoniou, K. M., Distler, O., Gheorghiu, A. M et al (2026). ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG). Annals of the rheumatic diseases, 85(1), 22\u201360. https:\/\/doi.org\/10.1016\/j.ard.2025.08.021","DOI":"10.1016\/j.ard.2025.08.021"},{"issue":"11","key":"1776_CR8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen\u00a0F, Khanna\u00a0D, Fransen\u00a0J et\u00a0al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72(11):1747\u20131755. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1776_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","volume":"201","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Tashkin\u00a0DP, Denton\u00a0CP et\u00a0al (2020) Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am J Respir Crit Care Med 201(6):650\u2013660. https:\/\/doi.org\/10.1164\/rccm.201903-0563CI","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1776_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/thoraxjnl-2012-201786","volume":"68","author":"CJ Stock","year":"2013","unstructured":"Stock\u00a0CJ, Sato\u00a0H, Fonseca\u00a0C et\u00a0al (2013) Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68(5):436\u2013441. https:\/\/doi.org\/10.1136\/thoraxjnl-2012-201786","journal-title":"Thorax"},{"issue":"2 Suppl","key":"1776_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/2397198320903867","volume":"5","author":"SI Nihtyanova","year":"2020","unstructured":"Nihtyanova\u00a0SI, Denton\u00a0CP (2020) Pathogenesis of systemic sclerosis associated interstitial lung disease. J\u00a0Scleroderma Relat Disord 5(2 Suppl):6\u201316. https:\/\/doi.org\/10.1177\/2397198320903867","journal-title":"J Scleroderma Relat Disord"},{"issue":"6","key":"1776_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00408-021-00494-y","volume":"199","author":"D Klay","year":"2021","unstructured":"Klay\u00a0D, van der Vis\u00a0JJ, Roothaan\u00a0SM et\u00a0al (2021) Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease. Lung 199(6):659\u2013666. https:\/\/doi.org\/10.1007\/s00408-021-00494-y","journal-title":"Lung"},{"issue":"6","key":"1776_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41431-018-0104-8","volume":"26","author":"CJW Stock","year":"2018","unstructured":"Stock\u00a0CJW, Renzoni\u00a0EA (2018) Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur J Hum Genet 26(6):765\u2013777. https:\/\/doi.org\/10.1038\/s41431-018-0104-8","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"1776_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.semarthrit.2010.10.002","volume":"41","author":"A Ludwicka-Bradley","year":"2011","unstructured":"Ludwicka-Bradley\u00a0A, Silver\u00a0RM, Bogatkevich\u00a0GS (2011) Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum 41(2):212\u201322. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.10.002","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1776_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheumatol 23(5):581\u2013590. https:\/\/doi.org\/10.1002\/art.1780230510","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1776_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1148\/radiol.2322031223","volume":"232","author":"SR Desai","year":"2004","unstructured":"Desai\u00a0SR, Veeraraghavan\u00a0S, Hansell\u00a0DM et\u00a0al (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiol Imaging Cancer 232(2):560\u2013567. https:\/\/doi.org\/10.1148\/radiol.2322031223","journal-title":"Radiology"},{"issue":"10354","key":"1776_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","volume":"400","author":"M Wijsenbeek","year":"2022","unstructured":"Wijsenbeek\u00a0M, Suzuki\u00a0A, Maher\u00a0TM (2022) Interstitial lung diseases. Lancet 400(10354):769\u2013786. https:\/\/doi.org\/10.1016\/S0140-6736(22)01052-2","journal-title":"Lancet"},{"issue":"1","key":"1776_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-019-0980-7","volume":"20","author":"V Cottin","year":"2019","unstructured":"Cottin\u00a0V, Brown\u00a0KK (2019) Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 20(1):13. https:\/\/doi.org\/10.1186\/s12931-019-0980-7","journal-title":"Respir Res"},{"issue":"5","key":"1776_CR19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02026-2019","volume":"55","author":"O Distler","year":"2020","unstructured":"Distler\u00a0O, Assassi\u00a0S, Cottin\u00a0V et\u00a0al (2020) Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 55(5):1902026. https:\/\/doi.org\/10.1183\/13993003.02026-2019","journal-title":"Eur Respir J"},{"issue":"2","key":"1776_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1378\/chest.13-2626","volume":"146","author":"TA Winstone","year":"2014","unstructured":"Winstone\u00a0TA, Assayag\u00a0D, Wilcox\u00a0PG et\u00a0al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146(2):422\u2013436. https:\/\/doi.org\/10.1378\/chest.13-2626","journal-title":"Chest"},{"issue":"5","key":"1776_CR21","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1378\/chest.15-0003","volume":"148","author":"CJ Ryerson","year":"2015","unstructured":"Ryerson\u00a0CJ, O\u2019Connor\u00a0D, Dunne\u00a0JV et\u00a0al (2015) Predicting Mortality in Systemic Sclerosis-Associated Interstitial Lung Disease Using Risk Prediction Models Derived From Idiopathic Pulmonary Fibrosis. Chest 148(5):1268\u20131275. https:\/\/doi.org\/10.1378\/chest.15-0003","journal-title":"Chest"},{"issue":"6","key":"1776_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/rheumatology\/kew480","volume":"56","author":"A Ariani","year":"2017","unstructured":"Ariani\u00a0A, Silva\u00a0M, Seletti\u00a0V et\u00a0al (2017) Quantitative chest computed tomography is associated with two prediction models of mortality in interstitial lung disease related to systemic sclerosis. Rheumatology 56(6):922\u2013927. https:\/\/doi.org\/10.1093\/rheumatology\/kew480","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1776_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00408-018-0126-6","volume":"196","author":"RL Mango","year":"2018","unstructured":"Mango\u00a0RL, Matteson\u00a0EL, Crowson\u00a0CS, Ryu\u00a0JH, Makol\u00a0A (2018) Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease. Lung 196(4):409\u2013416. https:\/\/doi.org\/10.1007\/s00408-018-0126-6","journal-title":"Lung"},{"issue":"11","key":"1776_CR24","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina\u00a0A, Walker\u00a0KM, Pope\u00a0JE, Scleroderma Algorithm Group (2018) Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol 70(11):1820\u20131828. https:\/\/doi.org\/10.1002\/art.40560","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"1776_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s13023-021-01844-y","volume":"16","author":"E Hachulla","year":"2021","unstructured":"Hachulla\u00a0E, Agard\u00a0C, Allanore\u00a0Y et\u00a0al (2021) French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis 16(Suppl 2):322\u2013322. https:\/\/doi.org\/10.1186\/s13023-021-01844-y","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1776_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2397198318779532","volume":"4","author":"RB Blank","year":"2019","unstructured":"Blank\u00a0RB, Nwawka\u00a0OK, Yusov\u00a0AA, Gordon\u00a0JK (2019) Inflammatory arthritis in systemic sclerosis: What to do? J\u00a0Scleroderma Relat Disord 4(1):3\u201316. https:\/\/doi.org\/10.1177\/2397198318779532","journal-title":"J Scleroderma Relat Disord"},{"issue":"7","key":"1776_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1136\/ard.53.7.434","volume":"53","author":"P Barrera","year":"1994","unstructured":"Barrera\u00a0P, Laan\u00a0RF, van Riel\u00a0PL et\u00a0al (1994) Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 53(7):434\u2013439. https:\/\/doi.org\/10.1136\/ard.53.7.434","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1776_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0049-0172(87)90021-7","volume":"16","author":"CW Carson","year":"1987","unstructured":"Carson\u00a0CW, Cannon\u00a0GW, Egger\u00a0MJ, Ward\u00a0JR, Clegg\u00a0DO (1987) Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 16(3):186\u2013195. https:\/\/doi.org\/10.1016\/0049-0172(87)90021-7","journal-title":"Semin Arthritis Rheum"},{"issue":"1\u20132","key":"1776_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/17476348.2024.2329612","volume":"18","author":"M Harrison","year":"2024","unstructured":"Harrison\u00a0M, Kavanagh\u00a0G, Corte\u00a0TJ, Troy\u00a0LK (2024) Drug-induced interstitial lung disease: a\u00a0narrative review of a\u00a0clinical conundrum. Expert Rev Respir Med 18(1\u20132):23\u201339. https:\/\/doi.org\/10.1080\/17476348.2024.2329612","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"1776_CR30","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00337-2020","volume":"57","author":"PA Juge","year":"2021","unstructured":"Juge\u00a0PA, Lee\u00a0JS, Lau\u00a0J et\u00a0al (2021) Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 57(2):2000337. https:\/\/doi.org\/10.1183\/13993003.00337-2020","journal-title":"Eur Respir J"},{"issue":"1","key":"1776_CR31","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2174\/187153008783928334","volume":"8","author":"M Shenin","year":"2008","unstructured":"Shenin\u00a0M, Naik\u00a0M, Derk\u00a0CT (2008) The use of mycophenolate mofetil for the treatment of systemic sclerosis. Endocr Metab Immune Disord Drug Targets 8(1):11\u201314. https:\/\/doi.org\/10.2174\/187153008783928334","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"9","key":"1776_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ et\u00a0al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719. https:\/\/doi.org\/10.1016\/S2213-2600(16)30152-7","journal-title":"Lancet Respir Med"},{"issue":"7","key":"1776_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann\u00a0ER, Tashkin\u00a0DP, Li\u00a0N et\u00a0al (2017) Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. Arthritis Rheumatol 69(7):1451\u20131460. https:\/\/doi.org\/10.1002\/art.40114","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1776_CR34","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu\u00a0G, Rochwerg\u00a0B, Zhang\u00a0Y et\u00a0al (2015) An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American journal of respiratory and critical care medicine 192(2):e3\u2013e19","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"26","key":"1776_CR35","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M et\u00a0al (2019) Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med 380(26):2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"1776_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102211","volume":"64","author":"H Bukiri","year":"2022","unstructured":"Bukiri\u00a0H, Volkmann\u00a0ER (2022) Current advances in the treatment of systemic sclerosis. Curr Opin Pharmacol 64:102211. https:\/\/doi.org\/10.1016\/j.coph.2022.102211","journal-title":"Curr Opin Pharmacol"},{"key":"1776_CR37","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna\u00a0D, Denton\u00a0CP, Jahreis\u00a0A et\u00a0al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387:2630\u20132640. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"key":"1776_CR38","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Lin\u00a0CJF, Furst\u00a0DE, Goldin\u00a0J, Kim\u00a0G, Kuwana\u00a0M et\u00a0al (2020) Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 8:963\u2013974. https:\/\/doi.org\/10.1016\/S2213-2600(20)30318-0","journal-title":"Lancet Respir Med"},{"issue":"6","key":"1776_CR39","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1164\/rccm.202103-0714OC","volume":"205","author":"D Khanna","year":"2022","unstructured":"Khanna\u00a0D, Lin\u00a0CJF, Furst\u00a0DE et\u00a0al (2022) Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med 205(6):674\u2013684. https:\/\/doi.org\/10.1164\/rccm.202103-0714OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"SI","key":"1776_CR40","doi-asserted-by":"publisher","first-page":"SI143","DOI":"10.1093\/rheumatology\/keac435","volume":"62","author":"A Kuzumi","year":"2023","unstructured":"Kuzumi\u00a0A, Yoshizaki\u00a0A, Mitsuo\u00a0S, Miyake\u00a0T, Sato\u00a0S (2023) Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis-associated interstitial lung disease. Rheumatology 62(SI):SI143\u2013SI144. https:\/\/doi.org\/10.1093\/rheumatology\/keac435","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1776_CR41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.6982","volume":"12","author":"PA Gouveia","year":"2020","unstructured":"Gouveia\u00a0PA, Ferreira\u00a0ECG, Cavalcante Neto\u00a0PM (2020) Organizing Pneumonia Induced by Tocilizumab in a Patient with Rheumatoid Arthritis. Cureus 12(2):e6982. https:\/\/doi.org\/10.7759\/cureus.6982","journal-title":"Cureus"},{"issue":"Suppl 2","key":"1776_CR42","doi-asserted-by":"publisher","first-page":"s57","DOI":"10.7861\/clinmed.20-2-s57","volume":"20","author":"S Silva","year":"2020","unstructured":"Silva\u00a0S, Amarasena\u00a0R, Moorcroft\u00a0J, Rajakulenthiran\u00a0T, Singh\u00a0R (2020) Tocilizumab-induced pulmonary fibrosis in a patient with rheumatoid arthritis. Clin Med (Lond) 20(Suppl 2):s57\u2013s57. https:\/\/doi.org\/10.7861\/clinmed.20-2-s57","journal-title":"Clin Med (Lond)"},{"key":"1776_CR43","doi-asserted-by":"crossref","unstructured":"Ariani, A., Aiello, M., Silva, M et al (2017). Quantitative CT indexes are significantly associated with exercise oxygen desaturation in interstitial lung disease related to systemic sclerosis. The clinical respiratory journal, 11(6), 983\u2013989. https:\/\/doi.org\/10.1111\/crj.12451","DOI":"10.1111\/crj.12451"}],"updated-by":[{"DOI":"10.1007\/s00393-026-01863-9","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000}}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01776-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-026-01776-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-026-01776-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T05:31:37Z","timestamp":1787808697000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-026-01776-7"}},"subtitle":["A\u00a0case report and a\u00a0literature review","Fallbericht und Literatur\u00fcbersicht"],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1007\/s00393-026-01776-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"14 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: In the Discussion section, the statement starting with \u201cHowever, the focuSSced trial,\u201d was made erroneously.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An Erratum to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00393-026-01863-9","URL":"https:\/\/doi.org\/10.1007\/s00393-026-01863-9","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.\u00a0Chen, X.\u00a0Li, D.\u00a0Huang, P.\u00a0Chen, P.\u00a0Xu, H.\u00a0Chen, and X.\u00a0Zhang declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Eighth Affiliated Hospital of Sun Yat-sen University.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient has signed written informed consent.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to publish. All authors have read and approved the final work.","order":5,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}